Latest Breaking News On - Sosei group corporation the company - Page 6 : comparemela.com

Sosei Heptares Webinar Presentation for FY2022 Financial Results

Sosei Heptares Webinar Presentation for FY2022 Financial Results - read this article along with other careers information, tips and advice on BioSpace

United kingdomEleanor perkinFrazer hallChris cargillNeurocrine biosciencesSosei heptaresHironoshin nomuraCandelle chongGenentech rocheShinichiro nishishitaCompany home pageSosei group corporationSosei groupSosei group corporation the companyTokyo stock exchangeMedistrava consulting for international media

Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substa

Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by So.

United kingdomMatt barnesSosei heptaresMark fishmanTempero bioJoe jimenezSosei heptareAditum bioUs national institute on drug abuseSosei group corporation the companyClearance to advance clinical developmentSosei heptares notesPartner tempero bioAdvance clinical developmentSubstance useDrug abuse

Sosei Heptares Partner Pfizer Progresses its Oral GLP-1

PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trialsDosing of first subject in Phase 2.

United kingdomEleanor perkinFrazer hallNeurocrine biosciencesSosei heptaresHironoshin nomuraCandelle chongMatt barnesGenentech rocheShinichiro nishishitaSosei group corporationSosei groupSosei group corporation the companyTokyo stock exchangeMedistrava consulting for international mediaGroup corporation

Sosei Heptares Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity

Sosei Heptares Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomEleanor perkinFrazer hallNeurocrine biosciencesSosei heptaresMatt barnesDisclosurescandelle chongGenentech rocheSosei heptaresweRelationshironoshin nomuraShinichiro nishishitaSosei group corporationMedistrava consulting for international media mark swallowSosei groupSosei group corporation the companyTokyo stock exchange

Sosei Heptares to present at 41st Annual J P Morgan Healthcare Conference

Sosei Heptares to present at 41st Annual J P Morgan Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomSan franciscoUnited statesEleanor perkinFrazer hallChris cargillNeurocrine biosciencesSosei heptaresDisclosurescandelle chongGenentech rocheSosei heptaresweRelationshironoshin nomuraShinichiro nishishitaCompany home pageSosei group corporationMedistrava consulting for international media mark swallow